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Viruses are ubiquitous and can infect any of the three existing cellular lineages (Archaea, Bacteria and
Eukarya). Despite the persisting negative public perception of these entities, scientists learnt how to
domesticate some of them. The study of molecular mechanisms essential to the completion of viral cycles
has greatly contributed to deciphering fundamental processes in biology. Nowadays, viruses have entered the
biotechnological era and numerous applications have already been developed. Viral-derived tools are used to
manipulate genetic information, detect, diagnose, control and cure infectious diseases, or even design new
structural assemblies. With the recent advances in the ﬁeld of metagenomics, an overwhelming amount of
information on novel viruses has become available. As current tools have been historically developed from a
limited number of viruses, the potential of discoveries from new archaeal, bacterial and eukaryotic viruses
may be limited only by our understanding of the multiple facets of viral cycles.
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Amongst the earliest applications of viruses, their use as live or
attenuated particles to develop vaccines during the 19th century
was very important as it represented the beginning of taming
viruses for our purposes, but is beyond the scope of this review.
Beside this major contribution to human health, exploitation of
viruses ramped up with the discovery of viruses infecting bacteria
named bacteriophages. One of the earliest applications of these
bacterial viruses was proposed by d’Herelle, who demonstrated
almost 100 years ago that bacteriophages were able to cure humanll rights reserved.
Debarbieux).bacterial infections (d’Herelle, 1917). This therapeutic approach,
bacteriophage therapy, rapidly developed globally until the indus-
trial production of antibiotics was launched in the 1940s (Summers,
2001). Around the same time, Delbru¨ck and colleagues chose
bacteriophages as model organisms to understand the genetic basis
of virus–host interactions (Luria and Delbruck, 1943). Soon after,
the larger scientiﬁc community adopted these viruses and their
hosts, and studies performed during the following 40 years yielded
a tremendous amount of literature (Fig. 1), allowing major dis-
coveries notably in both DNA and RNA processes shared by living
organisms. Altogether, these ﬁndings led to the development of the
ﬁrst molecular tools and ultimately to the advent of a new
discipline, now called molecular biology (Summers, 1999).
It is remarkable that such a vast array of discoveries were founded
on studies performed on a very limited number of bacteriophages
Fig. 1. Rise and fall of bacteriophage publications over a century (search in
Pubmed performed in June 2012 and percentages calculated from the number of
hits bearing the term ‘‘phage’’ over 10 year periods).
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than 20). For example, to our knowledge, the Lambda bacteriophage,
one of the best studied temperate bacteriophages, was once isolated
almost inadvertently from E. coli and never again from an environ-
mental source, and numerous genetic tools have been derived from
this unique virus (Hendrix and Casjens, 2006). Transduction,
described by Lederberg in the 1950s, was amongst the ﬁrst techni-
ques exploiting bacteriophage abilities to recombine with host DNA
(Zinder and Lederberg, 1952). Since then, bacteriophage recombi-
nases have been extensively studied leading to the classiﬁcation of
these enzymes into two families: the lambda integrase group (with a
conserved tyrosine residue) and the serine recombinase group (with a
conserved serine residue) which includes the phiC31 integrase (Smith
et al., 2010). In both groups, some of these enzymes were further
used to develop tools to manipulate genomes not only within their
original host but also outside the bacterial world. For instance,
recombination genes of Lambda led to the development of in vitro
techniques to perform directed gene replacement in fungi
(Chaveroche et al., 2000). A recent development of the use of PhiC31
integrase in the long-term expression of transgenes in mammalian
cells may become an important tool for human gene therapy (Chavez
and Calos, 2011; Keravala et al., 2008). After the huge contribution of
a very limited number of different bacteriophages in the unveiling of
numerous molecular mechanisms conserved through cellular life, the
current development of viral metagenomics is likely to increase the
number of applications exploiting viral genes (Schoenfeld et al.,
2010). In this article we review some of the most recent applications
covering viral proteins, virion structures, full viruses and highlight
some future directions.Exploiting the speciﬁcity
One of the main hallmarks of viruses is their speciﬁcity for their
target. In many environments, viruses are exposed to a plethora of
hosts and their capacity to infect only a limited number of them
drives their population expansion and maintenance. This outstand-
ing property has therefore been exploited in numerous applications
among which bacteriophage typing was the ﬁrst to be widely used.
The susceptibility to different bacteriophages provides an easy way
to classify closely related bacterial strains. Bacteriophage typing
was introduced in the 1940s and despite the development of
molecular techniques, it is still being used, for example, by the
Health Protection Agency (UK) to type Salmonella and Staphylococ-
cus aureus strains (http://www.hpa.org.uk/). This is in fact not so
surprising since molecular techniques based on the presence/absence of DNA fragments do not take into consideration the
expression of proteins coded by these fragments, as well as the
activity of these proteins. In contrast, bacteriophages rely on the
presence/absence of molecular motifs expressed at the surface of
bacteria and remain useful tools to provide a rapid answer,
generally within a day, which is valuable in an outbreak situation
(Sechter et al., 2000). However, it may not be long before the price
of the latest sequencing technologies drops to the point where a full
genome sequence will become available within a couple of days,
thus rendering obsolete the bacteriophage typing activity.
It is clear that the rapid and accurate identiﬁcation of bacterial
pathogens is vital in order to prevent the spread of infections and
limit their consequences by implementing appropriate control stra-
tegies. This is a particularly important concern for hospitals, care
centres and in the food industry. Several bacteriophages have been
exploited for technology development to enable the rapid detection
of bacteria in complex environments, in particular through the use of
bacteriophage based probes (Hagens and Loessner, 2007; Rees and
Dodd, 2006; Ripp, 2010; Singh et al., 2012; Smartt et al., 2012).
However, very few diagnostic kits for the detection of pathogens in
human samples such as the FASTPlaqueTB assay and the MRSA/MSSA
Blood Culture Test have yet reached the market (Stanley et al., 2007),
(http://www.microphage.com/technology/). The current applications
of bacteriophages in pathogen detection can be divided into two
groups: those based on inert bacteriophage particles or isolated
bacteriophage proteins and those that require an on-going infectious
cycle. Both systems have been developed targeting E.coli 0157:H7,
a major food pathogen. One of them, based on the speciﬁcity of a
bacteriophage tail protein, is already available on the market (VIDAS
UP E. coli O157, Biome´rieux). Brieﬂy, in this assay, a bacteriophage
speciﬁc for E. coli 0157:H7 was isolated, its tail ﬁbre protein was
identiﬁed and produced as a recombinant peptide, labelled with
a ﬂuorescent dye and included into the VIDAS sandwich assay
technology. Another ingenious device using infective particles this
time was also designed. Combining horseradish peroxidase-labelled
bacteriophage with a serogroup-speciﬁc immunomagnetic separation
system and enrichment broth, it allows pre-ampliﬁcation of the
pathogen before its detection by a luminometer (Willford et al.,
2011). Among the viral proteins exploited for the detection of hosts,
we can distinguish between tail ﬁbre proteins as mentioned above,
required for the early step of the infectious cycle, and endolysins used
for bacteriophage release, the last step of the cycle. The use of tail
ﬁbre proteins relies on the speciﬁcity of a bacteriophage protein
towards its bacterial receptor. Other examples of such proteins in
pathogen detection include the receptor binding protein (RBP) of a
Campylobacter bacteriophage and the P22 tailspike protein conju-
gated to nanoaggregate embedded beads (Tay et al., 2012).
Endolysins, participate in the lysis of the host cell by degrading
speciﬁc bonds within the bacterial peptidoglycan in order for the
bacteriophage progeny to be released at the end of the lytic cycle.
Endolysins reported to date are either globular or modular. Modular
endolysins display at least one N-terminal catalytic domain and a
C-terminal cell wall binding domain (Fischetti, 2008; Loessner,
2005). The cell wall binding domain (CBD) of a speciﬁc endolysin
shows high speciﬁcity and afﬁnity for its ligand on the cell wall of
its host, readily accessible in Gram positive bacteria. This speciﬁcity
has been exploited in various techniques, in particular for detection.
One example is an assay in which CBDs of Listeria monocytogenes,
Bacillus cereus or Clostridium perfringens were coated onto para-
magnetic beads, allowing a better separation and recovery of
bacterial cells than with standard techniques (Kretzer et al., 2007).
Applications requiring an infectious particle may use labelled
particles as described above but may also be based on genetically
modiﬁed bacteriophages leading to the expression of a reporter
gene that is highly expressed upon bacteriophage infection. Exam-
ples of these reporter bacteriophages include those carrying
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which Vibrio harveyi luxAB genes were inserted immediately down-
stream of the gene encoding the major capsid protein, or bacter-
iophages for Yersinia pestis and Bacillus anthracis in which a similar
approach proved efﬁcient in detecting these two pathogens, whose
rapid diagnosis is crucial in the ﬁght against bioterrorism (Loessner
et al., 1996; Schoﬁeld et al., 2011). Other types of reporter genes can
also be inserted in bacteriophage genomes, such as a hyperthermo-
philic b-glycosidase gene used for the detection of Listeria cells
(Hagens et al., 2011). The main advantage of the latter is that the
overtime signal ampliﬁcation goes on as long as the substrate is
provided, long after the host has been lysed.
Finally, one may simply use the lytic nature of the bacterioph-
age as the ‘‘sensor’’ to detect of the presence of the host. This is
the principle of the FASTPlaqueTB assay for the detection of
Mycobacterium tuberculosis in sputum in which bacteriophages
infecting the slow-growing tubercle bacillus are subsequently
detected when forming plaques on a fast-growing strain (Rees
and Loessner, 2005). This technique can also be coupled to a
molecular tool for higher speciﬁcity as in the phage-IS900
technique used to detect viableMycobacterium avium paratuberculosis
in dairy products, a pathogen thought to have a role in Crohn’s
disease pathogenesis (Botsaris et al., 2010).
By deﬁnition, these detection systems are designed to be
disposable and single use kits, therefore the nature of the key
components (sometimes genetically modiﬁed) does present
safety issues, and their usage will have to be constrained within
an appropriate waste management protocol. In addition, these
systems often developed for one particular host can be adapted
for many others upon identiﬁcation of the corresponding genes or
proteins in bacteriophage genomes, which nevertheless, can be
sometimes difﬁcult when working with a new bacteriophage
(typically a new bacteriophage possesses over 70% of ORFs that
do not match any ORFS present in genomic databank).
Apart from pathogen detection applications, the viral speciﬁ-
city may also be used for targeted delivery such as gene delivery
to a target cell for therapeutic purposes. Genetically engineered
bacteriophages used as vectors for nucleic acids may target
bacterial or eukaryotic cells. For example, non-lytic ﬁlamentous
bacteriophages can be used to deliver genes encoding proteins
that are toxic to their bacterial host, such as the delivery of
‘‘addiction toxins’’ triggering programmed cell death via M13
phagemid system (Hagens and Blasi, 2003; Westwater et al.,
2003). The use of a non-lytic bacteriophage presents the advan-
tage of killing the bacterial cell while leaving it intact, thereby
limiting the release of bacterial endotoxins and decreasing the
resulting inﬂammation (Hagens et al., 2004).
Among virus-derived applications of gene delivery to eukar-
yotic cells, one can cite adeno-associated virus AAV works
towards therapy for lung cancer via the delivery of the CD40L
gene, or studies using Herpes-simplex virus for the transfer of the
C3 transferase gene to indirectly promote axonal regeneration
(Wu et al., 2007; Zhou et al., 2012b). Bacteriophages also have a
potential in gene therapy via transfection of genes toxic for cancer
cells. This could be a promising future strategy for treating
advanced lung and colon cancer, combining gene transfer with
chemotherapeutic agents (Rama et al., 2011).Exploiting bacteriophages for biocontrol purposes
In the environment, viruses play a major role as biocontrol
agents for their hosts and do so through either one of the two life
cycle strategies they use. A bacteriophage will either infect its
host to immediately produce its progeny leading to the death of
the host (virulent cycle), or it may delay the progeny productionby staying silent within its host genome for a number of genera-
tions (temperate cycle). For obvious reasons, bacteriophages
displaying a temperate nature are not suitable for use in the
development of biocontrol strategies. Strictly lytic viruses, how-
ever, are very much appropriate for biocontrol downstream
applications. The process of infecting and efﬁciently killing their
bacterial hosts has been reﬁned over billions of years of evolution
and shows a great versatility in overcoming possible resistance
mechanisms that a bacterium could evolve (Labrie et al., 2010).
This type of bacteriophage has indeed been broadly exploited for
the biocontrol of bacteria for human, industrial or ecological
interests.
The alarming problem of the increasing occurrence of anti-
biotic resistant bacteria has recently revived the interest in
bacteriophage therapy. Despite the fact that human bacterio-
phage treatment has been carried out over the last 80 years in
Eastern Europe, the evolution of safety and regulation standards
in Western countries during the last 30 years is currently
preventing the development of large scale clinical trials due to
the lack of recent data on both efﬁcacy and safety (Maura and
Debarbieux, 2011). Nevertheless, within the last decade, an
increasing number of proof of concept studies were achieved
using animal models. As for human testing, one phase II clinical
trial using the Biophage-PA bacteriophage preparation towards
antibiotic-resistant Pseudomonas aeruginosa in 24 patients with
chronic otitis was published, concluding to its safety and efﬁcacy
(Wright et al., 2009). Another trial, supported by the Nestle´
Nutrition Corporate and involving the oral administration of T4
bacteriophages in young children with diarrhoea due to ETEC/
EPEC infections, is currently being carried out and is due to
completion in 2014 (Clinical Trial Identiﬁer NCT00937274).
Biocontrol of pathogens in food products may represent an
economically viable ﬁeld for bacteriophage-based biocontrol. This
topic was extensively reviewed (Garcia et al., 2008; Goodridge
and Bisha, 2011; Hagens and Loessner, 2010; Mahony et al.,
2011). Many studies reported success in decreasing the bacterial
load (for Listeria, Salmonella and E. coli species among others) on
food surfaces (cheese and meat), hard surfaces and also cattle
hide (Anany et al., 2011; Coffey et al., 2011; Guenther et al., 2012;
Viazis et al., 2011; Viscardi et al., 2008). Several systems have
already been approved by authorities for use on food products
such as ListShieldTM (Intralytix) or LISTEXTM (Micreos) for the
control of L. monocytogenes (both FDA- and USDA-approved),
EcoShieldTM (FDA-cleared) targeting E. coli O157:H7 and SALMO-
NELEXTM against Salmonella which also beneﬁciated from a
Temporary Use Exemption by the Dutch Medicine Evaluation
Board for the currently ongoing ﬁeld trials. Bacteriophages were
also found to be efﬁcient for the decontamination of livestock
raised for the food industry, therefore limiting the risk of pathogens
reaching the food chain, or to detect the presence of pathogens in
animal-derived alimentary products. Bacteriophages have shown
success in control of plant pathogens too with recent examples
including the development of a bacteriophage-based biocontrol
technique for Dickeya solani, a bacterium which causes potato
plants to waste, and the effective prevention of wilting using a
cocktail of three lytic bacteriophages for the bacterium Ralstonia
solanacearum (Adriaenssens et al., 2012; Fujiwara et al., 2011).
The company Omnilytics developed the bacteriophage product
‘‘Agriphage’’ for the control of bacterial spot caused by Xantho-
monas campestris or bacterial speck caused by Pseudomonas
syringae (www.omnilytics.com). The effectiveness of this product
in protecting the crops against these pathogens is reﬂected by
the report of a marked increase in yield. However, early sugges-
tions that bacteriophage interaction with plants might actually
decrease plant growth or not show improvements compared to
regular treatments are also reported, highlighting the need for
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mentation is considered (Gill and Abedon, 2003; Jones et al.,
2007; Kocharunchitt et al., 2009; Ye et al., 2009).
Finally bacteriophages are currently being investigated for
their potential as natural biocontrol agents for environmental
issues. Their natural presence in the environment would suggest a
lower risk of natural ecology disturbance, making them an
attractive alternative to chemicals as antibacterial agents. In this
ﬁeld, works have been carried out in the context of wastewater
treatment and sludge processing. Only a few studies have been
conducted so far but encouraging results in foam, sludge volume
or biomass bulking reduction were reported (Choi et al., 2011;
Kotay et al., 2011; Petrovski et al., 2012).
Besides the use of entire bacteriophage particles, the use of
isolated proteins has also raised interest lately. The use of single
gene products by-passes the difﬁculties of using infective parti-
cles and tends to reassure the community by eliminating the risk
of genetic recombination and general instability linked to the idea
of using viruses while keeping the beneﬁt of the main hallmark of
the bacteriophage, that is to say its speciﬁcity.
As mentioned earlier, endolysins cleave peptidoglycan bonds
enabling them to lyse Gram positive bacteria when applied
externally. The potential use of these proteins as antimicrobial
agents has been extensively reviewed (Coffey et al., 2010; Fenton
et al., 2010; Fischetti, 2008; Fischetti, 2010; O’Mahony et al.,
2011). More recently, the production of recombinant lysins
(engineered or chimeric lysins) has also been achieved in a
number of studies (Pastagia et al., 2011; Resch et al., 2011;
Schmelcher et al., 2012). Their antimicrobial potential against
S. aureus, B. anthracis, Streptococcus pneumoniae, Enterococci,
L. monocytogenes or Clostridiumdifﬁcile to cite only a few, is well
documented (Kikkawa et al., 2008; Mayer et al., 2008; Rashel
et al., 2007; Rodriguez-Cerrato et al., 2007; Yoong et al., 2004;
Zhang et al., 2012a). Most recent advances in the ﬁeld of chimeric
lysins led to the design of a hybrid protein targeting Gram
negative pathogens, whose structure is templated on a bacterial
toxin called pesticin. It is composed of T4 lysozyme fused to the
domain of pesticin targeting FyuA, an outer membrane transpor-
ter but also a major virulence factor for some Yersinia and
pathogenic E. coli strains. This hybrid lysin has therefore the
potential to cross the outer membrane of pathogens to gain access
to the peptidoglycan, and was shown to be able to kill speciﬁc
Yersinia and pathogenic E. coli strains (Lukacik et al., 2012).Fig. 2. Rising of phage display and bacteriophage therapy related publications (percenta
therapy related topics over the past two decades). (Search in Pubmed performed in Sept
‘‘phage display’’, or ‘‘phage’’ together with ‘‘therapy’’).Following infection, the bacteriophage quickly hijacks the host
cellular machinery to its own proﬁt in order to redirect it to the
production of the proteins that will constitute its progeny. To do
so more efﬁciently, bacteriophages often encode early proteins
inhibiting the processing of the host proteins. Several of these
early proteins have been identiﬁed by different groups and their
implication in antibacterial compounds investigation has been
reviewed by Sau et al. (2008). Examples of such proteins include
peptides inhibiting bacterial replication by interacting with the
host DNA replication proteins, peptides inhibiting the cell wall
synthesis such as the Kil proteins in coliphages Mu or Lambda and
peptides interfering with bacterial transcription by inhibiting the
synthesis of the host proteins however preserving the synthesis of
their own (Nechaev and Severinov, 2008).
When the bacteriophage protein does not have a bactericidal
action in itself, it can also be fused to a bactericidal agent in order
to direct the latter to its target. This approach was used success-
fully by Scholl et al., who fused the O-antigen-speciﬁc bacterio-
phage tail spike gene identiﬁed in the genome of the O104:H4 E.
coli strain, to a Pseudomonas pyocin to obtain an engineered
bacteriocin displaying a speciﬁc activity against the O104:H4
serotype (Scholl et al., 2012).Exploitation of bacteriophage structural properties
Due to their high level of organisation, viruses represent
elaborate nanomachines. In particular, ﬁlamentous bacterio-
phages, that can be easily genetically manipulated, have been
the focus of many studies and allowed the development of
bacteriophage display techniques (Fig. 2). An increasing number
of applications in the ﬁeld of nanotechnology is driving many
researchers to exploit bacteriophage properties among which we
can distinguish their use as vectors or as matrices for new
nanotechnological devices with a wide array of applications in
nanomedicine (Fan et al., 2012; Hemminga et al., 2010; Hyman,
2012; Rakonjac et al., 2011).
Viral/phage display
Phage display, the principles of which are detailed in several
reviews involves the engineering of the bacteriophage in order for
the virus to carry foreign molecules on its surface throughges of the total ‘‘phage’’ publications dedicated to phage display and bacteriophage
ember 2012 and percentages calculated from the number of hits bearing the terms
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techniques (Pande et al., 2010; Sidhu et al., 2000).
The use of a bacteriophage to display foreign peptides was ﬁrst
reported in 1985 by Smith and since then, the relevance of this now
famous system has found numerous applications in different
domains including epitope identiﬁcation, antigen delivery, drug
discovery, vaccine design, targeting of eukaryotic cells, bioimaging
and biosensing, enzyme display or nanomaterials design (Adda
et al., 2002; Ahmadvand et al., 2011; Collins et al., 2006; Gao et al.,
2010; Li et al., 2010; Molek et al., 2011; Prisco and De Berardinis,
2012; Seker and Demir, 2011; Smith, 1985; Szardenings, 2003).
Numerous viral platforms are used for displaying molecules at
the surface of a virus particle, either through molecular manip-
ulation or through chemical modiﬁcation. These include eukar-
yotic viruses systems such as the cowpea mosaic and potato
X viruses, TMV, turnip yellow mosaic virus or bacteriophage
based systems with M13, Qb, Lambda, T7 or T4 (Banerjee et al.,
2010; Chatterji et al., 2002; Dunn, 1995; Pande et al., 2010; Ren
et al., 1996; Smith et al., 2009; Sokoloff et al., 2000; Steinmetz
et al., 2010; Sternberg and Hoess, 1995; Zan et al., 2012).Principles: Display through molecular manipulation or chemical
modiﬁcation
Molecular engineering of the bacteriophage genome is wide-
spread and has been implemented for display in four main
bacteriophage systems: T4, T7, Lambda, and ﬁlamentous bacterio-
phages (Beghetto and Gargano, 2011; Gupta et al., 2003; Hemminga
et al., 2010; Kehoe and Kay, 2005; Kurzepa et al., 2009; Meng et al.,
2011; Rakonjac et al., 2011; Teesalu et al., 2012). In this approach,
the gene introduced into the bacteriophage genome codes for a
peptide that is expressed as a protein fusion on the bacteriophage
surface. This technique is widely used in numerous ﬁelds of science
for its potential of large scale screening as the inserted genetic
information can be randomly generated to produce a library,
achieve targeted delivery to speciﬁc locations or study molecule
interactions. This display approach has been extensively applied to
the M13 ﬁlamentous bacteriophage. M13 is an 880 nm long rod
shaped, single-stranded DNA virus. Its viral capsid is composed of
2700 copies of helically arranged major coat protein (pVIII) and 5–7
copies of pIII, pVI, pIX and pVII, located at either of its ends
(Petrenko et al., 1996; Smith and Petrenko, 1997).
Since its beginnings, the phage display technique and its
application within the framework of libraries allowed the screening
of a wide array of molecules based on their speciﬁcity or binding
afﬁnity to various compounds and the selection of ligands to
virtually any target. Brieﬂy, the antigen of interest is immobilized
on a surface and exposed to the engineered bacteriophage library.
The bacteriophage particles displaying on their surface a molecule
with afﬁnity for the immobilized antigen will therefore bind and
the rest of the library will be washed away. The bound fraction can
be eluted and ampliﬁed resulting in a mixture of bacteriophage
particles displaying the relevant molecule. This procedure is
repeated in a process called ‘biopanning’ and allows the identiﬁca-
tion of molecules with high binding afﬁnity to the antigen of
interest. This technique is widely applied and resulted in the
identiﬁcation of numerous molecules of interest with afﬁnity to
other peptides, nucleic acid fragments, carbohydrates but also
plastic and polystyrene, or inorganic substances with interesting
physicochemical properties (Adey et al., 1995; Vodnik et al., 2012)
However, the bacteriophage library concept also presents
limitations. For example, the ampliﬁcation of the libraries during
which bacteriophage candidates are ampliﬁed in the bacteria,
leads to a certain level of competition between numerous bacter-
iophage clones thus resulting in the loss of library diversity. This
therefore restricts the number of ligands that can be identiﬁed inone screen and may represent a severe constraint for targets with
multiple binding sites (Derda et al., 2011).
One should also bear in mind that the displayed peptide size and
charge should be taken into account as they inﬂuence the number
of peptides that can be displayed on the surface of a virion. In order
to retain a good bacteriophage production during ampliﬁcation, the
normal processing of the bacteriophage coat protein should indeed
not be hindered by the fused peptide in order to allow its correct
expression and to let the protein fulﬁl it biological role in the
bacteriophage replication process (Imai et al., 2008). Following
these observations, Merzlyak and Lee published a method using
degenerate ﬂanking residues, to express functional but unfavour-
able peptide motifs on major coat protein pVIII of bacteriophage
M13 while limiting the bacterial biological censorship involved in
the natural pVIII protein processing during the bacteriophage
replication (Merzlyak and Lee, 2009).
Alternatively, viruses can also be ‘‘decorated’’ with molecules by
means of chemical modiﬁcation in a process called bioconjugation
(Gillitzer et al., 2002). This technique has been utilized for the binding
of peptides (CPMV), polymers (adenoviruses), carbohydrates (CPMV)
but also proteins and nucleic acids via surface functionalization as for
MS2 and Qb bacteriophages capsids (Chatterji et al., 2004; O’Riordan
et al., 1999; Patel and Swartz, 2011; Raja et al., 2003; Sen Gupta et al.,
2005). Binding of inorganic molecules such as gadolinium chelate
groups (MS2 bacteriophage capsid) was also achieved (Anderson
et al., 2006). This approach allows the attachment of molecules on the
outside but also the decoration of the inside of the protein
shell, for example for the use of viral particles for cargo transport
(Kovacs et al., 2007). The use of archaeal viruses, such as SIRV2 whose
surface can also be functionalized, represents an interesting option
due to the extremophile nature of the hosts conferring these viruses
with an outstanding stability in harsh physical conditions (tempera-
ture, pHy), making them attractive for applications in nanotechnol-
ogies (Steinmetz et al., 2008).Main applications
Since the display technique was discovered, a tremendous
amount of studies have been carried out (Fig. 2). One can observe
a marked increase in the published literature for 20 years and
then, the plateau could suggest that we may have reached a limit
in the number of new applications derived from this technique.
This approach is now used in various domains of science such as
in antiviral research, novel therapeutics and vaccine design,
cancer research, targeted delivery, imaging or nanotechnologies
to cite only a few ranging from biology to nanotechnologies
(Castel et al., 2011; Gao et al., 2010; Huang et al., 2012; Hyman,
2012; Li et al., 2010; Ronca et al., 2012; Staquicini et al., 2010;
Yamashita et al., 2010). Exhaustive information can be found in
numerous articles, book chapters or scientiﬁc reviews on the
technique itself (Bratkovic, 2010; Miller et al., 2010; Rentero and
Heinis, 2011; Smith and Petrenko, 1997; Vodnik et al., 2011).
A selection of applications from different domains is listed in
Table 1.
The display technique involving chemical conjugation is widely
used for detection purposes through the binding of contrast agents,
of biotin–streptavidin systems for conjugation of peptide-displaying
bacteriophages to quantum dots or of ﬂuorescent dyes for bioima-
ging or biosensing purposes (Anderson et al., 2006; Edgar et al.,
2006; Li et al., 2010). To cite one example, T4 heads were used as
scaffolds for the conjugation of Cy3 and Alexa Fluor 546 ﬂuorescent
dyes in order to design virus based nanoparticles suitable for cell
imaging (Robertson et al., 2011). This conjugation technique can
also be applied to proteins after surface functionalization as demon-
strated for MS2 and Qb VLPs or to DNA as shown for M13
bacteriophage (Lee et al., 2012b; Patel and Swartz, 2011). In some
Table 1
Example of the main applications of phage display.
Principle Putative application Reference Bacteriophage
Peptide
identiﬁcation
Identiﬁcation of tumour homing peptides Tumour cell targeting Pasqualini and Ruoslahti (1996), Rivinoja and Laakkonen (2011) M13/T7
E.g. RGD-4C Peptide (cancer cell targeting) Arap et al. (1998, 2002)
Identiﬁcation of organ-homing peptides Organ targeting Pasqualini (1999) M13
E.g. PSMA (prostate-speciﬁc membrane antigen) Antigen detection Arter et al. (2012)
or TGN (peptide targeting the drug delivery
system to the brain)
Targeted drug delivery across the
blood brain barrier when bound to
nanoparticles
Li et al. (2011)
Identiﬁcation of white fat vasculature homing
peptide
Control of obesity Kolonin et al. (2004) M13
Identiﬁcation skin/membrane-permeable
peptide
Alzheimer’s therapy Zhang et al. (2010)
Identiﬁcation of skin penetrating and cell
entering peptide
Treatment of various skin diseases Hsu and Mitragotri (2011) M13
Identiﬁcation of peptides binding to organic
crystals
Modiﬁcation of surface chemistry of
the crystals—application in agriculture
Cho et al. (2012) M13
Identiﬁcation of short peptides mimicking
carbohydrates conformation, lectin mimics
Glycobiology—Anti-carbohydrate
antibodies production—discovery of
biomimetic peptides against
carbohydrate and lectin targets
Fukuda (2012), Gerlach et al. (2010), Yu et al. (2009) M13
Identiﬁcation of peptides able to bind to
inorganic materials
Applications in electronics and
opticals—bacteriohage-based
electrodes and batteries -
nanotechnologies
Whaley et al. (2000), Nam et al. (2006), Nam et al. (2008) M13
Peptide display Display of antigenic peptides Peptide Vaccines design Gao et al. (2010) T4, T7, Lambda,
ﬁlamentous
bacteriophages
E.g. the EFRH epitope Elicits humoral response in Alzheimer’s
patients
Solomon (2008)
Integrin-binding peptides Tissue-regeneration matrices Chung et al. (2010)
Display of speciﬁc antigen binding peptides
(PSMA-speciﬁc peptide)
Biodetection by bacteriophage-based
electrodes
Yang et al. (2006)
Bacteriohage probes Detection of viral and bacterial
pathogens
Goldman et al. (2000, Petrenko and Sorokulova (2004)
Dye-labelled peptide-displaying bacteriophages Sensing of environmental pollutants Goldman et al. (2002) M13
Peptide delivery Display of a peptide inducing endocytosis and a
peptide interfering with the pathogen
Potential therapeutic strategy to
prevent or reduce sexually
transmissible diseases
Bhattarai et al. (2012) M13
Display of antibody
or antibody
fragments
Peptide delivery coupled to display of an
antibody/antibody fragment
Targeted antigen delivery system to
professional APCs—application in new
vaccines design
Prisco and De Berardinis (2012) fd
Display of cocaine-sequestering antibodies Drug addiction control Dickerson et al. (2005) Filamentous phage
Display of engineered monoclonal antibodies
able to enter the CNS
Alzheimer’s disease therapy Solomon (2008) Filamentous
bacteriophage
Display of llama single-domain antibodies
(sdAbs)
Drug transport across the BBB Muruganandam et al. (2002) M13
Display of antibody fragments binding cell
surface receptors in a manner that leads to
endocytosis
Entry into mammalian cells, targeted
gene delivery
Poul and Marks (1999) F5
Display of antibody variable region Production of recombinant anti-
carbohydrate antibodies
Fukuda (2012) M13
Display of antibody fragments against viruses Tools for diagnosis and serotyping of
dengue
Cabezas et al. (2009) M13
Carbohydrate display Display of HIV-related glycans HIV glycan-based vaccine design Astronomo et al. (2010) Qb
Enzyme display Display of alpha-amylase and xylanase enzymes De-inking of ofﬁce waste Zachariou et al. (2006) T7
Display of bioﬁlm-degrading enzymes Bioﬁlm degradation Collins et al. (2006) Various
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chemical modiﬁcation of its surface can be coupled, as previously
demonstrated for EGF-displaying Qb particles subsequently conju-
gated with a ﬂuorescent dye for visualization of cellular attachment
and uptake monitoring (Pokorski et al., 2011).Bacteriophages and nanotechnologies
Peptide display by ﬁlamentous bacteriophage allowed the
identiﬁcation of molecules able to bind to inorganic materials
and eventually, peptides with selectivity for binding to metal
surfaces (Brown, 1997). Works by the team of A.M. Belcher show
how phage-display libraries can be used to obtain peptides that
bind to a range of semiconductor surfaces with high speciﬁcity,
depending on the crystallographic orientation and composition of
the material, in the view of using this principle with materials
important in electronics or optics (Whaley et al., 2000). Molecules
with such afﬁnities as well as the highly organised structure of
the bacteriophage particle are elements extensively exploited in
the construction of periodically ordered nanomaterials such as
nanometre-scale electronic and medical materials. This resulted
in the design of a model for the fabrication of a highly ordered
composite material from genetically engineered M13 bacterio-
phage and zinc sulphide nanocrystals (Lee et al., 2002). This led to
biotechnological advances as varied as the ‘‘creation’’ of ﬁlms,
ﬁbres, or nanowires with applications in the assembly of materi-
als for lithium ion battery electrodes, photochemical devices and
even improved catalysts through the templating of nickel, rho-
dium, and ceria onto the surface of the M13 bacteriophage
(Huang et al., 2005; Lee et al., 2009; Mao et al., 2003; Mao
et al., 2004; Merzlyak et al., 2009; Nam et al., 2006; Nam et al.,
2008; Nam et al., 2010a; Nam et al., 2010b; Neltner et al., 2010).
Most recently published works on genetically engineered M13
describe the possibility of generating piezoelectric energy as well
as nanorods and nanowires ranging from 300 nm to micron sizes
which may ﬁnd uses in nanoelectronics, sensing, and cancer
therapy (Lee et al., 2012a; Zhou et al., 2012a).
In addition, inorganic molecules assembled into electronic and
magnetic particles led to the construction of biomedically relevant
materials such as artiﬁcial bone substance created through the
mineralization of a nanoﬁber constituted bundle of M13 bacter-
iophage or liquid-crystalline ﬁlm matrices able to control and guide
cell behaviour for tissue-regenerating applications (Chung et al.,
2010; He et al., 2010; Merzlyak et al., 2009; Xu et al., 2011).
Bacteriophage proteins/scaffold
Cargo
The bacteriophage capsid is built from a number of protein
subunits assembled together. Already extensively used for the
display of molecules or material assembly, this protein scaffold
can also be used for its structure i.e. as a cage to entrap
biomolecules of interest. An ideal construct needs to deliver
relevant biomolecules on command to a speciﬁc target while
avoiding the neutralization by the immune system. Several of
these steps have already been achieved by different groups. For
example, the modiﬁcation of the internal and external surfaces of
the bacteriophage MS2 capsid to turn it into an efﬁcient drug
delivery system was described (Kovacs et al., 2007). In this
particular study, ﬁrst, extensive PEGylation of the capsids effec-
tively reduced the neutralization by antibodies. Second, the
binding of a ligand (biotin for example) to the distal ends of the
polymer chains (PEG) indicated the possibility to attach targeting
molecules to direct the cargo to a speciﬁc target. This approach
could be applied to various ligands with speciﬁc tissue targeting
properties (Weissleder et al., 2005). Third, the encapsidation oflarge ‘‘druglike’’ molecules was achieved. The synthesis of such
modiﬁed particles demonstrates the potential of this system for
efﬁcient drug delivery. More recently, another study reported the
synthesis of MS2 particles that could speciﬁcally deliver a number
of molecules such as nanoparticles, drugs, siRNAs or toxins to
hepatocellular carcinoma cells via the co-display of a targeting
peptide and a fusogenic peptide promoting endosomal escape
(Ashley et al., 2011). Finally, controlled release of a high-copy
cargo from engineered P22 capsids through morphological
changes induced by a change in temperature was described
(O’Neil et al., 2011).
Phi29 motor
Phi29 is another example of a virus which has been exten-
sively used in the ﬁeld of nanosciences (Zhang et al., 2012b). More
precisely, the DNA packaging motor of Phi29, required to package
double stranded DNA into the procapsid, has been studied in
depth at the molecular level. This motor that uses ATP to push
DNA into the procapsid requires only three components, the gp10
(connector) and gp16 proteins and a small packaging RNA (pRNA).
In vitro association of puriﬁed recombinant proteins and artiﬁ-
cially synthesized RNA was sufﬁcient to reconstitute an active
motor. This system led to the development of a wide variety of
applications as the bionanomotor can be turned on and off on
demand (absence/presence of ATP). In addition, not only the
motor itself but its individual components such as the connector
and the pRNA present molecular characteristics (oligomerization)
for which several applications in nanotechnologies have been
proposed (Ye et al., 2012).Perspectives
In half a century of research on viral-derived applications,
many molecular tools were developed that helped decipher
fundamental biological processes. Following this ‘‘golden age’’
(Fig. 1), the scientiﬁc community’s interest shifted towards ‘‘more
complex’’ systems. However, in the past decade, two main ﬁelds
have revitalized the interest for viruses-derived approaches. On
one hand, the advent of nanotechnology that showed many
promises based on purely chemical processes is now diversifying
towards bionanotechnology for which viruses have been the ﬁrst
biological entities to be used. On the other hand, the impressive
reduction in the cost of DNA sequencing now allows the production
of a massive amount of data from the analysis of environmental
samples. The main hurdle to overcome for the identiﬁcation of
viruses from genomic data is the presence of many unknown
sequences within new viral genomes, currently preventing an
accurate assembly of short reads. These data are only starting to
be exploited for the deciphering of viral variety and progressively
uncovering the extent of its diversity. Analysis of these metage-
nomic studies vastly broadens our current knowledge on viral
specimens and lifestyle (Krupovic and Forterre, 2011). Sequence
assembly issues resulting from short reads should shortly be solved
by the next generations of sequencing technologies. Meanwhile,
much can be learned from proteins identiﬁed with improved
techniques and through the presence of conserved domains such
as in DNA polymerases or endolysins (Schoenfeld et al., 2010).
However if a virus has evolved with a different mechanism from
those already known, there is a risk that it will be missed by this
approach. While these two domains are still being developed, they
carry the potential to increase the number of potential virus-
derived applications. For example, DNA polymerases with new
combination of properties (proofreading, thermostability, helica-
sey) could be identiﬁed. It could also be anticipated that amongst
new viruses identiﬁed by sequencing, some display enough
M. Henry, L. Debarbieux / Virology 434 (2012) 151–161158homology between regions comprising a number of unknown
genes, to be grouped. Looking deeper within these conserved
regions might suggest ORFs to be studied in priority for a given
function, the easiest ones being those related to the hijacking of the
host machinery as these proteins are not often speciﬁc to one
particular host. As well as contributing to reduce the proportion of
unknown genes within bacteriophage genomes, cloning these ORFs
in model organisms such as E. coli or S. aureus could reveal new
antibacterial activities whose mechanisms would inspire the ela-
boration of new drugs.
The recent discovery of giant viruses has revolutionized the
vision of low complexity associated with viruses (Koonin and
Yutin, 2010; Raoult et al., 2004). Carrying in their genome a large
amount of genetic information coding for elements usually
hijacked from the host, these viruses could become platforms to
further develop new tools able to support a higher degree of
complexity than bacteriophages, such as host-independent
processes.
The rate of identiﬁcation of previously unreported organisms
increased markedly with the development of metagenomics,
suggesting that numerous hosts and their viruses present in the
environment are yet to be discovered. To identify them, the use of
microﬂuidic PCR to link viruses to their hosts in environmental
samples without cultivating them has been recently developed
(Tadmor et al., 2011). In particular, this approach applied to the
human gut could reveal the degree to which viruses and their
hosts interplay in this complex polymicrobial environment.
Sequencing the viriome of the human gut has already revealed
the prominent contribution of prophages to genetic exchanges
(Reyes et al., 2010; Reyes et al., 2012). In contrast, virulent
bacteriophages appear underrepresented suggesting that the gut
environment may be unfavourable to them. On the other hand,
data obtained in a mouse model showed continuous replication of
virulent bacteriophages over several weeks suggesting a high
level of complexity in the relationship between bacteriophage
and host populations in the gut environment (Maura et al., 2012).
Several studies have also shown that in vitro polymicrobial
bioﬁlms can be reduced by bacteriophages (Brussow, 2012;
Donlan, 2009; Siringan et al., 2011). However these systems are
not yet similar enough to real situations, such as in medical and
environmental settings, to claim that bacteriophages can efﬁ-
ciently reduce bioﬁlms on their own. One solution may come
from a combinatorial approach where a bacteriophage infecting
one species may also code for hydrolytic enzymes targeting the
extracellular matrix produced by this species or others (Lu and
Collins, 2007). Such complex environments including various
cellular types represent a challenge for viruses and one may ask
whether, to some extent, this lifestyle developed, as a form of
resistance to viral attack.
Combination of activities might be a future direction in which
viruses-derived tools versatility could play an important role.
In particular, one can imagine designing a virus targeting for
example a gram negative host and carrying genes that are toxic
for gram positive species (such as endolysins) or fungi. Coupling
these different properties may offer the possibility to come up
with new highly efﬁcient broad antimicrobial strategies. With the
advent of in vitro synthesis of small genomes such approaches are
theoretically feasible and, according to progress in synthetic
biology, could have a broader impact than currently appraised
on the development of future applications (Wimmer et al., 2009).
However, there are two main limitations to such a concept: (1) an
extensive knowledge on viruses intended to be used as platforms
should be achieved; (2) speciﬁc guidelines should be deﬁned to
regulate the use of these viral recombinants. Nevertheless, it
might be possible that such chimeric viruses exist or have existed
in nature at some point but have been lost due to evolutionarypressure. The dynamics of the viral world are indeed so high that,
to date not a single gene has been identiﬁed that is conserved
amongst all bacteriophages sequenced (Liu et al., 2006). Their
genome plasticity, one of the trademarks of viruses, is such that
they are continuously creating new answers to the recurring
problem of the necessity of infecting their host, thus representing
a source of pressure for biological innovations that humans are
trying to exploit for their own interest.References
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